Intended for healthcare professionals

Naevi and melanoma

Rachel Jacoby, James Crane, FIonna Martin and Sandeep Varma
There are 8,000 new cases a year of malignant melanoma in the UK, with 1,800 deaths, making it the most serious skin cancer despite being one of the least common. Recognition and early referral to dermatologists is paramount in achieving the best prognosis. However, it is not always easy to differentiate benign lesions from malignant ones. Of all the benign lesions confused for malignant melanoma, melanocytic naevi (MN) feature prominently. Greater awareness of the classical features of both naevi and melanoma will minimise misdiagnoses.
Dermatology in practice 2007; 15(1): 21–24
To continue reading this article, please sign in or register.

Dermatology in practice was previously supported by Wyeth from 2008 to 2010, by Wyeth and Serono in 2007, by Wyeth and Shire from 2005 to 2006, by Medlock Medical in 2004 and by SSL International from 2001 to 2003.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the publisher, Editor or Editorial Board. Accordingly the publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Dermatology in practice is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2021 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 0262-5504 (Print) ISSN 2049-8446 (Online)